Massachusetts General Hospital investigators have found new evidence that the tumour necrosis factor receptor type II (TNFR2) may be a major target for immuno-oncology treatments, which induce a patient's immune system to fight cancer. TNFR2 is expressed...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2j6hI3o
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Purpose: Loss of volume in the sub-brow fat pad with associated descent of the eyebrow is a common anatomical finding resulting in both func...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Mingan Yu, Duqiang Liu, ...
-
Cachexia is a debilitating syndrome characterized by involuntary muscle wasting that is triggered at the late stage of many cancers. While t...
-
Abstract Endurance exercise generates CO 2 via aerobic metabolism; however, its role remains unclear. Exogenous CO 2 by transcutaneous d...
-
Publication date: Available online 13 April 2017 Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell Research Author(s): Marcos J...
-
Daily Mail Sarah was diagnosed with the cancer that killed Steve Jobs Daily Mail The symptoms Sarah Smith experienced on and off for...
-
Chapter 1 Introduction Background of the Study Cockroaches are common pests in the tropics. They have been known to cause allergic reactions...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2D1FTOq via IFTTT
-
Medicine by Alexandros G. Sfakianakis BioMed Research International BioMed Research InternationalTanshinone IIA Alleviates CCL2-Induced Le...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου